1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
Can You Come for a Visit? My ME/CFS Says No
My daughter and son-in-law just had a baby last week. We are thrilled. But we won't be able to see the baby or hold her any time soon. We won't be able to take over little gifts or help out with housework or babysitting.
Discuss the article on the Forums.

New drugs synchronize biological clock, boost endurance and muscle growth

Discussion in 'Other Health News and Research' started by Waverunner, Aug 22, 2013.

  1. Waverunner

    Waverunner Senior Member

    Messages:
    993
    Likes:
    836
    Until we know what CFS is and how it can be treated, these two new drugs could offer an alternative treatment option by resetting the biological clock, boosting endurance and muscle growth.

    http://www.scripps.edu/newsandviews/e_20130729/burris.html

    The study was published July 14, 2013, by the journal Nature Medicine.
    The drug candidate, SR9009, is one of a pair of compounds developed in the laboratory of TSRI Professor Thomas Burris and described in a March 2012 issue of the journal Nature as reducing obesity in animal models. The compounds affect the core biological clock, which synchronizes the rhythm of the body’s activity with the 24-hour cycle of day and night.
    The compounds work by binding to one of the body’s natural molecules called Rev-erbα, which influences lipid and glucose metabolism in the liver, the production of fat-storing cells and the response of macrophages (cells that remove dying or dead cells) during inflammation.
    In the new study, a team led by scientists at the Institut Pasteur de Lille in France demonstrated that mice lacking Rev-erbα had decreased skeletal muscle metabolic activity and running capacity. Burris’ group showed that activation of Rev-erbα with SR9009 led to increased metabolic activity in skeletal muscle in both culture and in mice. The treated mice had a 50 percent increase in running capacity, measured by both time and distance.
    “The animals actually get muscles like an athlete who has been training,” said Burris. “The pattern of gene expression after treatment with SR9009 is that of an oxidative-type muscle— again, just like an athlete.”
    The authors of the new study suggest that Rev-erbα affects muscle cells by promoting both the creation of new mitochondria (often referred to as the “power plants” of the cell) and the clearance of those mitochondria that are defective.

    http://www.novartis.com/newsroom/media-releases/en/2013/1723765.shtml
    Basel, August 20, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM).
    Breakthrough therapy designation was created by the FDA to expedite the development and review of new drugs for serious or life-threatening conditions. This designation is based on the results of a Phase II proof-of-concept study that showed BYM338 substantially benefited patients with sIBM compared to placebo. The results of this study will be presented at the American Neurological Association meeting on October 14 and is expected to be published in a major medical journal later this year.
    sIBM is a rare yet potentially life-threatening muscle-wasting condition. Patients who have the disease can gradually lose the ability to walk, experience falls and injuries, lose hand function, and have swallowing difficulties[1]. There are no currently approved, (or established), treatment options for sIBM[2].
    "BYM338 is the third example this year of Novartis' leadership in bringing breakthrough therapies to patients reinforcing our commitment to innovation addressing significant unmet medical needs and enhancing the lives of patients," said Timothy Wright, M.D., Global Head of Development, Novartis Pharmaceuticals. "With no effective therapies currently available for sIBM, bimagrumab has the potential to be the first real option for patients with this condition."
  2. alex3619

    alex3619 Senior Member

    Messages:
    7,019
    Likes:
    10,799
    Logan, Queensland, Australia
    My body clock is totally stuffed. The more we know about fixing it the better.
    Little Bluestem and Bob like this.
  3. taniaaust1

    taniaaust1 Senior Member

    Messages:
    7,865
    Likes:
    4,776
    Sth Australia
    That's something i wouldnt mind being in first trials to try. Running 50% more. sounds great, the rest too.
  4. Waverunner

    Waverunner Senior Member

    Messages:
    993
    Likes:
    836
    Yes, I fully agree with both of you. The good news is, that we will have lots of controls and experiences with these drugs because body-builders and athletics will probably use it a lot for doping. ;)
    biophile, jimmy86 and Marco like this.
  5. Sparrowhawk

    Sparrowhawk Senior Member

    Messages:
    447
    Likes:
    228
    West Coast USA
    Waverunner: Right, and slacker video gamers will also try this to get buff while couch surfing.
    Waverunner likes this.
  6. heapsreal

    heapsreal iherb 10% discount code OPA989,

    Messages:
    7,150
    Likes:
    4,408
    australia (brisbane)
    there was another drug orexin i think which was suppose to have been coming out soon but this was awhile ago that i heard this. It seems that anything outside of the traditional thinking of sleep meds is hard to make or get approved.
    I wish big pharma would step up to the plate and come out with some new sleep meds.

    cheers!!!
    Waverunner likes this.

See more popular forum discussions.

Share This Page